Lumida
/URGN
⌘K
Urogen Pharma Ltd

Urogen Pharma Ltd

URGN
$42.31USD+0.17%+0.07 today

MARKET CAP

2.1B

P/E (TTM)

FWD P/E

DAY RANGE

$42 – $44

52W RANGE

$16
$51

AI Summary

Stalk
Sell NowMedium

URGN has resumed a Stage 4 downtrend, driven by the Post-Parabola Collapse pattern and declining EMAs. Medium-term bias is bearish as price makes lower highs and lows and remains below the 9- and 20-day EMAs. Short-term momentum is negative, with price failing at near-term resistance and tracking lower. The momentum-oriented strategy favors continuation participation on rallies into the 9/20 EMA resistance zone (~44.8–45). Initiate Sell Now into that area and avoid chasing further declines.

  • Q2 revenue forecast of $62.8M, marking sequential top-line growth
  • EPS loss narrowing to $0.28 indicates improving financial momentum
  • Sustained $0.28 EPS loss underscores persistent profitability challenges
Full analysis →

Buying

6

institutions

Selling

6

institutions

New Positions

3

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
BI

Blackrock, Inc.

Q2 2026

BUY3.20 M117.81 M+355.89 K+130.3%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

BUYNEW1.53 M56.14 M+1.53 M+0.0%0.06%
WP

Woodline Partners LP

Q2 2026

SELL500.73 K18.43 M+-500.73 K+2.3%0.06%
AC

Adar1 Capital Management, LLC

Q2 2026

SELL252.40 K9.29 M+-143.06 K+30.6%0.43%
AC

Aqr Capital Management LLC

Q2 2026

BUY149.23 K5.49 M+5.17 K+112.0%0.00%
VI

Voloridge Investment Management, LLC

Q2 2026

SELL111.14 K4.09 M+-119.49 K-1.4%0.02%
MM

Millennium Management LLC

Q2 2026

SELL106.69 K3.93 M+-264.21 K-41.1%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL80.28 K2.95 M+-235.91 K-48.0%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUYNEW70.30 K2.59 M+70.30 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY39.54 K1.43 M+18.42 K+297.2%0.00%
JH

Janus Henderson Group Plc

Q1 2026

BUYNEW38.20 K686.26 K+38.20 K+0.0%0.00%
MG

Man Group Plc

Q2 2026

SELL0.000.00+-25.39 K-100.0%0.00%